Recent advancements in exosome screening methods, including microfluidic chips, surface-enhanced Raman scattering nanotags, and DNA aptamer-mediated microfluidics, offer simplified and time-saving approaches to profile exosome Epithelial Cell adhesion Molecule (EpCAM) and HER2 proteins, particularly for the diagnosis of HER2 + BC. This evidence concerns the gene EPCAM and breast cancer.